Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncothyreon has said that the US Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development.
Subscribe to our email newsletter
The newly issued patent includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867. The preclinical development for PX-867 has focused on cardiovascular disease. In particular, the compound has demonstrated activity as a coating on intravascular stents in preclinical models of atherosclerotic disease.
Robert Kirkman, president and CEO of Oncothyreon, said: “We intend to seek a partner to develop PX-867 in non-oncology indications, particularly in cardiovascular applications, while focusing our internal development efforts on PX-866 in oncology, our core area of expertise. We expect to file an investigational new drug application for PX-866 in the coming quarter and to initiate a Phase I trial soon thereafter.”